Guoming Hu1, Feng Xu2, Kefang Zhong2, Shimin Wang3, Qi Xu4, Liming Huang2, Pu Cheng5. 1. Department of General Surgery (Breast and Thyroid Surgery), Shaoxing People's Hospital (Shaoxing Hospital, Zhejiang University School of Medicine), Shaoxing, 312000, Zhejiang, China. hgmplj@126.com. 2. Department of General Surgery (Breast and Thyroid Surgery), Shaoxing People's Hospital (Shaoxing Hospital, Zhejiang University School of Medicine), Shaoxing, 312000, Zhejiang, China. 3. Department of Nephrology, Shaoxing People's Hospital (Shaoxing Hospital, Zhejiang University School of Medicine), Shaoxing, 312000, Zhejiang, China. 4. Department of Surgical Oncology, Shaoxing Second Hospital, Shaoxing, 312000, Zhejiang, China. 5. Department of Gynecology, Second Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang University, Hangzhou, 310009, China. drchengpu@zju.edu.cn.
Abstract
BACKGROUND: Systemic inflammatory response (SIR) plays important roles in initiation, promotion and progression of tumor. However, the prognostic role of preoperative circulating neutrophil-lymphocyte ratio (NLR) (known as a marker of SIR) in human primary bladder cancer (BC) undergoing radical cystectomy (RC) remains controversial. Hence, we performed this meta-analysis to better understand the role of preoperative circulating NLR in prognosis prediction for primary BC patients undergoing RC. METHODS: We searched PubMed, Embase and EBSCO to identify the studies and computed extracted data with STATA 12.0. RESULTS: A total of 11,945 patients with BC from 18 published studies were incorporated into this meta-analysis. We found that elevated NLR was significantly associated with decreased 3-year and 5-year overall survival (OS), 1-year, 3-year and 5-year recurrence-free survival (RFS), but not with 1-year or 10-year OS, or 10-year RFS in primary BC patients who underwent RC. The results also showed that neoadjuvant chemotherapy (NAC) had a significant impact on the negative prognostic effect of NLR. In addition, high NLR significantly correlated with unfavorable clinicopathological features of BC. CONCLUSION: Elevated preoperative circulating NLR leads to an unfavorable outcome in primary BC undergoing RC, especially in patients without NAC, implicating that it might be a valuable prognostic index for these patients.
BACKGROUND: Systemic inflammatory response (SIR) plays important roles in initiation, promotion and progression of tumor. However, the prognostic role of preoperative circulating neutrophil-lymphocyte ratio (NLR) (known as a marker of SIR) in human primary bladder cancer (BC) undergoing radical cystectomy (RC) remains controversial. Hence, we performed this meta-analysis to better understand the role of preoperative circulating NLR in prognosis prediction for primary BC patients undergoing RC. METHODS: We searched PubMed, Embase and EBSCO to identify the studies and computed extracted data with STATA 12.0. RESULTS: A total of 11,945 patients with BC from 18 published studies were incorporated into this meta-analysis. We found that elevated NLR was significantly associated with decreased 3-year and 5-year overall survival (OS), 1-year, 3-year and 5-year recurrence-free survival (RFS), but not with 1-year or 10-year OS, or 10-year RFS in primary BC patients who underwent RC. The results also showed that neoadjuvant chemotherapy (NAC) had a significant impact on the negative prognostic effect of NLR. In addition, high NLR significantly correlated with unfavorable clinicopathological features of BC. CONCLUSION: Elevated preoperative circulating NLR leads to an unfavorable outcome in primary BC undergoing RC, especially in patients without NAC, implicating that it might be a valuable prognostic index for these patients.
Authors: Boyd R Viers; Stephen A Boorjian; Igor Frank; Robert F Tarrell; Prabin Thapa; R Jeffrey Karnes; R Houston Thompson; Matthew K Tollefson Journal: Eur Urol Date: 2014-02-26 Impact factor: 20.096
Authors: L Spencer Krane; Kyle A Richards; A Karim Kader; Ronald Davis; K C Balaji; Ashok K Hemal Journal: J Endourol Date: 2013-08 Impact factor: 2.942
Authors: T Hermanns; B Bhindi; Y Wei; J Yu; A P Noon; P O Richard; J R Bhatt; A Almatar; M A S Jewett; N E Fleshner; A R Zlotta; A J Templeton; G S Kulkarni Journal: Br J Cancer Date: 2014-06-10 Impact factor: 7.640